Cereno will present the abstract “Investigation of efficacy, safety and optimal dose of CS1 in subjects with pulmonary arterial hypertension: a prospective, randomized, multicenter, parallel-group phase II study” at the 15th Annual World Congress on Pulmonary Vascular Disease in Athens, Greece, on June 22-26, 2022. It’s organized by the Pulmonary Vascular Research Institute (PVRI).
The abstract is a collaboration between Cereno, Dr. Raymond Benza, global PAH key opinion leader and principal investigator (PI) for the Phase II study and study collaborator Abbott. The abstract will be presented as a poster by Dr. Raymond Benza.